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To the Editor,
We read the recent article “Treatment of idiopathic
granulomatous mastitis and factors related with disease
recurrence” published by Tekgoz and colleagues with great
interest [1]. The authors stated that they aimed to investigate
the effect of immunosuppressive treatment on idiopathic
granulomatous mastitis (IGM) and risk factors related to
IGM recurrence.
We would like to emphasize a few important points
regarding the medical management algorithm of the present
study.
The authors state that they have applied a cross-sectional
retrospective research model in the present study. This
statement is wrong in terms of epidemiological aspect
because the studies that go from the outcome to the exposure
are retrospective case-control studies. The cross-sectional
studies evaluate the exposure and outcome at the same time
and are usually performed to determine the prevalence of
certain conditions or diseases. Other names of the study
method are epidemiological surveillance, transvers study,
screening, fact-findings survey, ad hoc survey, point-in-time
study, and one-shot survey.
The authors did not give any information regarding their
management protocol to patients with IGM. In Turkey, the
duration from admission to the histopathological diagnosis
of IGM is around 3–4 weeks. In patients with abscess and
cellulitis, it is not rational to wait for the biopsy result without
performing drainage and/or antibiotics. The current literature
suggests that drainage and antibiotics should be performed
to patients admitted with abscess and cellulitis. Also, patients
with inflammatory mass should receive antiinflammatory
treatment after the biopsy until the definitive results are
obtained. We would like to share our diagnostic and
therapeutic algorithm that we have deduced from our own
experiences and extensive review of the literature (Figure).
We believe it will contribute to the present study and this
extensive algorithm is first in the medical literature.
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The authors state that they have given methotrexate
(MTX; 10–15mg/week) treatment for a median of 9.1 months
together with concomitant steroid therapy (40 mg/day) for a
median of 9.6 months to 96.2% of the patients. As we have
contributed significantly and among the first surgeons who
have used MTX in the treatment of IGM, we recommend that
the first-line therapy of IGM should always begin with steroid
therapy [2,3]. However, we recommend the administration
of MTX occasionally azathioprine in patients who develop
complications (such as glucose intolerance, hypertension,
central obesity, and osteoporosis) due to steroid therapy, in
patients with poor response to steroid therapy, or in patients
who develop remission due to steroid therapy but develop
recurrence after discontinuation of steroid therapy. However,
MTX can be initiated as a first-line therapy in patients with
contraindications that use steroid therapy, but MTX therapy
should be initiated at a dose of 5 mg/week and the side effect
of the drug should be checked by routine blood tests. Briefly,
only a few researchers suggest the use of MTX or MTX plus
steroid as the first-line therapy; however, there is a consensus
on the use of steroid therapy before initiating MTX [2,4].
Long-term therapy of MTX and steroids for completely
benign disease should be evaluated carefully due to its
detrimental effects in patients with an age range of 20–40
years. Besides nearly 29–50% recurrence rates following
steroids or MTX treatment result in questioning the necessity
of steroids or MTX therapy in patients [4,5]. Therefore, one
of the radical surgical treatment options (partial or total
mastectomy-plus breast reconstruction) should be offered to
reproductive aged-patients who have recurred IGM disease
despite more than 2 cycles of steroid and MTX treatment.
Since it is necessary to inform the patients correctly about
the side effects of long-term immunosuppressive treatment
protocols.
The authors have made a misfortunate statement that
none of the imaging studies have any superiority over
biopsy. Pathologic analysis is a definitive diagnostic tool
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Figure. Diagnostic and therapeutic management algorithm for patients with IGM.

and expecting any other adjunctive diagnostic study to be
superior to a gold standard test is not logical. However,
studies can determine the sensitivity, specificity, and
predictive value of a given test per the gold standard
reference test which is histopathologic analysis.
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